How a novel pediatric gene therapy developer leveraged regulatory gap analysis to align with FDA expectations
By Tom Hallam, Ph.D., MBA
For emerging pharmaceutical companies navigating the road to U.S. market approval, the right nonclinical regulatory strategy, built with expert scientific and strategic guidance, can mean the difference between efficient progress and costly delays along the rare disease drug approval process.
The FDA meeting framework offers several distinct interaction types, each designed to serve a specific stage of product development. Understanding which meeting type applies to your situation is one of the most important early decisions a sponsor can make:
- Type A meetings: Reserved for stalled development programs
- Type B meetings: Milestone-based interactions (e.g., pre-IND, end of Phase 2)
- Type C meetings: A flexible forum for clarifying scientific or regulatory questions that arise at any point during development
- Type D meetings: Designed for rapid FDA input on focused issues
Among these FDA meeting types, the Type C meeting offers a uniquely strategic opportunity, particularly for those working in novel therapeutic modalities or rare pediatric indications where the science may outpace existing regulatory precedent.
In this post, we’re sharing a real-world example of how we supported a small pharma company through a nonclinical Type C meeting for a novel gene therapy targeting a fatal, rare pediatric neurodegenerative disorder — a condition where no other approved treatments existed.
Our team:
- Conducted a gap analysis and reviewed existing nonclinical data
- Provided the strategy around the engagement with the FDA, including recommending the best time to meet with the FDA, outlining the right strategic questions, and identifying and executing on the tactical steps to achieve FDA meeting success
- Led preparation and writing of the FDA Type C meeting materials
- Provided expert nonclinical regulatory advisory support throughout the process
Why Intentional Type C Meeting Strategy Matters for Rare Disease Drug Developers
Proactive and early communication with the agency, particularly through a well-executed Type C meeting strategy, can help sponsors align R&D activities with reviewer expectations before investing in costly studies.
Because Type C meetings are not milestone-dependent, they allow sponsors a unique opportunity to surface and resolve scientific or regulatory issues as they arise, rather than discovering misalignment during a formal review cycle.
This is especially critical in the rare disease drug approval process for pediatric innovations, where:
- Patient populations are limited
- Clinical development faces unique scientific challenges
- Misaligned nonclinical studies can create serious timeline and resource consequences
- The FDA often has flexibility to consider the totality of evidence, but only if it’s presented strategically
The Situation: A Critical Nonclinical Juncture in Pediatric Development
Our client was developing a novel gene therapy targeting a rare pediatric neurodegenerative disorder. Facet helped them clear the initial IND application and commence a Phase 1 clinical trial in healthy adults. As the program advanced in the clinic, a critical juncture arose in the nonclinical animal studies.
The core issue: The company had previously conducted a juvenile toxicity study in animals corresponding to patients aged 12-18 years. But with opportunities to expand future trials to younger pediatric patients (ages 2-12), significant questions emerged about what additional nonclinical data, if any, would be required to support that enrollment.
Facet’s Strategy: Analyzing Regulatory Gaps & Nonclinical Realities
Having identified three key questions that required FDA clarity, Facet’s nonclinical experts advised the client to seek additional guidance on their development:
- Whether additional juvenile nonclinical toxicity studies were needed to support the inclusion of 2-12 year-old patients in future trials
- Whether additional biodistribution and pharmacokinetic data in pediatric-age animal models would be required
- Whether certain toxicology studies could be waived, given the disease’s severity and the limited life expectancy of the patients involved
Given the novel therapeutic modality, the vulnerable patient population, and the risk of investing in misaligned or unnecessary nonclinical studies, Facet advised the sponsor to pursue a Type C meeting to clarify FDA expectations before committing pediatric dosing resources to additional nonclinical safety studies.
The Type C Meeting Submission & Outcome
Facet’s American Board of Toxicology (ABT)-certified nonclinical experts conducted a structured gap analysis of the sponsor’s existing nonclinical package. To support the sponsor’s position, we worked with them to prepare and submit a Type C meeting request based on the analysis findings, along with a detailed meeting background package, which summarized:
- The available nonclinical data collected to date
- The proposed nonclinical studies to support future clinical development
- Specific questions for FDA input with a scientific or regulatory rationale for each discussion topic
The FDA granted a Written Response Only (WRO) Type C meeting, a common outcome when FDA doesn’t feel an in-person or real-time (telcon or videoconference) interaction is necessary to provide detailed feedback.
FDA Feedback
The FDA’s written feedback provided the sponsor with actionable guidance on each regulatory question raised, validating the novel nonclinical strategy that Facet proposed in the gap analysis. Key reviewer responses made clear that:
- A juvenile animal study was required. Because the condition manifests in early infancy, the FDA confirmed that a juvenile animal study would be necessary prior to enrolling younger patients.
- The sponsor had some flexibility on biodistribution data. Developmental maturity data on target organs in the proposed animal models, combined with existing biodistribution data from adult animals, could be used in lieu of pediatric-specific biodistribution studies. This was a meaningful resource-saving determination.
- The reproductive toxicity waiver would be supported. The FDA indicated a waiver for reproductive toxicity studies was likely to be granted, recognizing that the target pediatric population was not expected to survive long enough to achieve reproductive potential. This confirmation of Facet’s strategy allowed the Sponsor to omit costly and time-consuming reproductive tox studies with confidence.
Before committing to any additional studies, the sponsor walked away from the meeting with a better understanding of how the current and future states of their rare disease development process met approval thresholds.
Impact: How the Type C Meeting Strategy Outlined a Clear Path Forward
This case illustrates how a proactive regulatory gap analysis paired with a well-prepared Type C meeting strategy can fundamentally reshape a development program’s trajectory. With Facet’s support, the sponsor:
- Avoided unnecessary studies, saving limited time and resources
- Designed a custom, scientifically sound nonclinical strategy based on insights from Facet’s gap analysis, and validated by formal FDA feedback
- Streamlined the development plan to include only the studies needed to support pediatric dosing in an efficient and targeted manner
- Earned explicit agency support for an innovative development approach built on an evidence-based meeting package
For a small company navigating the complex rare disease drug approval process, these outcomes represent the difference between a direct path to the clinic and months of misaligned effort and wasted resources.
Accelerating FDA Approval with Strategic Regulatory Advisory
The FDA submission process for novel therapeutics, especially for data in a rare pediatric disease setting, is not a linear checklist. It requires strategic thinking, scientific rigor, and the kind of proactive regulatory engagement that smaller developers often lack the internal bandwidth to execute alone.
What this case demonstrates is that for this product, getting to and through the FDA doesn’t require a full-blown 40+ study nonclinical development program. Instead, it required asking the right questions, at the right time, in the right way.
A targeted regulatory gap analysis can tell you where you stand. A well-executed Type C meeting strategy guides the path forward with agency-backed insights and agreements.
At Facet Life Sciences, we work as a true collaborative partner to emerging biotech, pharmaceutical, and device developers. We bring the scientific depth, regulatory experience, and submission leadership to help you navigate the FDA’s expectations and minimize the barriers between your science and the patients who need it.
Ready to Build Your Type C Meeting Strategy and Maximize Program Potential?
Whether you’re facing a unique nonclinical challenge, exploring an accelerated path for rare diseases, or simply trying to understand where your program stands relative to FDA expectations, our regulatory and development experts are ready to help you analyze, plan, and execute strategies that get it to and through the FDA the first time.
Need help planning your Type C FDA meeting or development strategy? Want to discuss your nonclinical development plan with a board-certified toxicologist with at least 15 years in regulated industries working with FDA? Can your R&D program be streamlined using information from a gap analysis? Drop a comment below or contact us directly to start a conversation.
| Request an Expert-Led Gap Analysis |
gET sOCIAL